KX2-391 dihydrochloride: Dual Src and Tubulin Inhibitor for Cancer and HBV Research

Executive Summary: KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) is a small-molecule inhibitor that acts via a dual mechanism, targeting both Src kinase and tubulin polymerization. It demonstrates potent inhibition of Src kinase with IC₅₀ values as low as 23 nM in NIH3T3/c-Src527F cells, and robust suppression of hepatitis B virus (HBV) transcription by disrupting the HBV precore promoter (Harada et al., 2017, https://doi.org/10.1016/j.antiviral.2017.06.005). KX2-391 also inhibits botulinum neurotoxin A (BoNT/A) activity via SNAP-25 cleavage at 10–40 μM. Clinically, it is used as a 1% ointment for actinic keratosis, with oral dosing reaching plasma peaks of 61–218 ng/mL. APExBIO provides high-purity, stable KX2-391 dihydrochloride (SKU A3535), supporting diverse experimental workflows (product page).

Biological Rationale

KX2-391 dihydrochloride is designed to simultaneously disrupt two critical biological pathways: the Src kinase signaling pathway and the tubulin polymerization pathway. Src family kinases are central regulators of oncogenic transformation, cell proliferation, and survival. Abnormal Src kinase activity is implicated in various cancers and resistant phenotypes. Tubulin polymerization is essential for mitotic spindle formation, making it a validated target in cancer therapeutics. HBV replication also exploits host tubulin dynamics for efficient transcription and genome maintenance (Harada et al., 2017). Thus, a dual inhibitor like KX2-391 offers an integrated approach to targeting oncogenic and viral processes.

Mechanism of Action of KX2-391 dihydrochloride

KX2-391 dihydrochloride operates via a dual mechanism:

• Src kinase inhibition: It binds to the substrate-binding site (not the ATP-binding pocket) of Src kinase, resulting in potent non-ATP-competitive inhibition. IC₅₀ values are 23 nM in NIH3T3/c-Src527F cells and 39 nM in SYF/c-Src527F cells at standard culture conditions (37°C, 5% CO₂).
• Tubulin polymerization inhibition: KX2-391 binds to a novel site on the α-β tubulin heterodimer, distinct from colchicine or vinca alkaloid sites, disrupting microtubule assembly. Inhibition is observed at ≥80 nM (Harada et al., 2017).
• HBV transcriptional suppression: The compound inhibits HBV transcription by targeting the precore promoter region, independent of HBV X protein activity. This effect is linked to its tubulin polymerization inhibition.
• BoNT/A inhibition: At concentrations of 10–40 μM, KX2-391 inhibits SNAP-25 cleavage mediated by Botulinum neurotoxin A, likely via direct interaction with the BoNT/A light chain.

Evidence & Benchmarks

• KX2-391 inhibits Src kinase with IC₅₀ values of 23 nM (NIH3T3/c-Src527F) and 39 nM (SYF/c-Src527F) at 37°C, 5% CO₂ (Harada et al., 2017).
• Disruption of tubulin polymerization requires ≥80 nM KX2-391 in cell-free in vitro assays (Harada et al., 2017).
• HBV suppression is documented with EC₅₀ values of 0.14 μM in PXB cells and 2.7 μM in HepG2-NTCP cells; selectivity index is 450 and >37, respectively (Harada et al., 2017).
• Anti-BoNT/A activity is demonstrated at 10–40 μM, with measurable inhibition of SNAP-25 cleavage in vitro (Harada et al., 2017).
• In vivo, effective oral dosing in mice is 5–15 mg/kg once or twice daily; in chimpanzees for anti-HBV, 1 mg/kg twice daily is reported (Harada et al., 2017).
• Clinically, a 1% ointment (10 mg/g) applied once daily for 5 days treats actinic keratosis with plasma C_max of 61–218 ng/mL; oral dosing for tumors is 40–120 mg/day (Harada et al., 2017).
• KX2-391 shows good tolerability, with low incidence of peripheral neuropathy in clinical studies (Harada et al., 2017).

For more on maximizing assay reproducibility with this inhibitor, see Maximizing Assay Reliability with KX2-391 dihydrochloride, which provides practical troubleshooting and benchmarking strategies; this article extends those findings by detailing the molecular mechanisms and precise pharmacological benchmarks.

For a focused discussion of translational and mechanistic insights, see KX2-391 Dihydrochloride: Mechanistic Insights and Emerging Applications; here, we further clarify how dual inhibition impacts HBV replication specifically.

Applications, Limits & Misconceptions

KX2-391 dihydrochloride is applied in:

• Cancer research: Evaluation of cell proliferation, migration, and apoptosis in Src-dependent tumor models.
• Antiviral studies: Suppression of HBV replication/transcription in hepatocyte-derived cell lines and in vivo models.
• Neurotoxin inhibition: BoNT/A enzymatic activity assays.
• Clinical dermatology: Topical treatment of actinic keratosis.

For a guide on integrating KX2-391 into routine cell viability and antiviral workflows, see Optimizing Cell-Based Assays with KX2-391 dihydrochloride; this article updates those strategies with new clinical tolerability and selectivity index data.

Common Pitfalls or Misconceptions

• Not a pan-kinase inhibitor: KX2-391 is selective for Src kinase and does not broadly inhibit other kinases at physiologically relevant concentrations.
• No direct cccDNA elimination: The compound suppresses HBV transcription but does not eliminate covalently closed circular DNA (cccDNA) reservoirs (Harada et al., 2017).
• Water insolubility: KX2-391 dihydrochloride is insoluble in water; DMSO or ethanol (with gentle warming) is required for preparation of stock solutions.
• Short-term solution stability: Solutions in DMSO or ethanol are recommended for immediate or short-term use only; long-term storage may impact potency.
• Not effective against all tubulin-dependent viruses: Its antiviral activity is specific to HBV; inhibition of other viruses is not established.

Workflow Integration & Parameters

Typical in vitro concentrations: 0.013–10 μM for anticancer/anti-HBV; 10–40 μM for anti-BoNT/A studies. Solubility: ≥25.2 mg/mL in DMSO; ≥48.8 mg/mL in ethanol (with gentle warming). Storage: -20°C; use fresh solutions for best results. In vivo dosing: 5–15 mg/kg (oral, mice); 1 mg/kg (oral, chimpanzee, anti-HBV). Clinical: 1% ointment (10 mg/g) for actinic keratosis; oral 40–120 mg/day for tumors. Effective plasma concentrations: ≥560 nM (241.92 ng/mL) for anti-HBV activity. Source and further technical details: KX2-391 dihydrochloride product page (APExBIO).

Conclusion & Outlook

KX2-391 dihydrochloride (Tirbanibulin dihydrochloride) stands out as a dual Src kinase and tubulin polymerization inhibitor with validated efficacy in oncology, virology, and neurobiology. Its molecular specificity, robust in vitro/in vivo benchmarks, and clinical tolerability profile make it a research tool of choice for dissecting Src and tubulin-driven pathways. Future studies may expand its utility to combinatorial regimens and mechanistic explorations beyond its current antiviral and anticancer applications.